Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088775 | 0.86 | HRH3 (0.48) | HRH3SIGMAR1CYP2D6OPRM1SLC6A2 | |
| SCHEMBL4505701 | 0.86 | HRH3 (0.48) | HRH3SIGMAR1CYP2D6OPRM1SLC6A2 | |
| SCHEMBL3877345 | 0.86 | HRH3 (0.48) | HRH3SIGMAR1CYP2D6OPRM1SLC6A2 | |
| SCHEMBL26955676 | 0.84 | CYP2D6 (0.60) | HRH3CYP2D6CYP19A1OPRM1OPRD1 | |
| SCHEMBL2537196 | 0.83 | MEN1 (0.58) | HRH3CYP2D6OPRM1OPRD1OPRL1 | |
| SCHEMBL2315253 | 0.83 | MEN1 (0.58) | HRH3CYP2D6OPRM1OPRD1OPRL1 | |
| SCHEMBL4146000 | 0.83 | MEN1 (0.58) | HRH3CYP2D6OPRM1OPRD1OPRL1 | |
| SCHEMBL14033487 | 0.83 | HRH3 (0.44) | HRH3ACHECYP2D6CYP19A1OPRM1 | |
| SCHEMBL23599969 | 0.82 | HRH3 (0.46) | HRH3SIGMAR1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL13723347 | 0.82 | HRH3 (0.46) | HRH3SIGMAR1CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-5703071-A | Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0546102-B1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES | UPJOHN CO (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5594144-A | TREATING CEREBROVASCULAR AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0283310-B1 | N-BENZHYDRYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE | Sankyo Company Limited (JP) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992004338-A1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES | THE UPJOHN COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| US-5028610-A | Calcium Channel Blockers | SANKYO COMPANY LIMITED (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0283310-A1 | N-Benzhydryl-substituted heterocyclic derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | HRH3 1275/4885ACHE 1285/4885SIGMAR1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.